Ansell Ltd
ASX:ANN

Watchlist Manager
Ansell Ltd Logo
Ansell Ltd
ASX:ANN
Watchlist
Price: 30.11 AUD -1.41% Market Closed
Market Cap: 4.4B AUD
Section:
Relative Value
Relative Value
Valuation Multiples
Multiples Across Competitors
See Also

Relative Value

The Relative Value of one ANN stock under the Base Case scenario is 40.86 AUD. Compared to the current market price of 30.11 AUD, Ansell Ltd is Undervalued by 26%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

ANN Relative Value
Base Case
40.86 AUD
Undervaluation 26%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

1.5
P/S
P/S
Price to Sales
1.5
vs History
44
vs Industry
52
Median 3Y
1.3
Median 5Y
1.4
Industry
2.2
Forward
1.4
More Details
25.4
P/E
P/E
Price to Earnings
25.4
vs History
19
vs Industry
21
Median 3Y
17.2
Median 5Y
17.2
Industry
21.9
Forward
16.1
More Details
10.4
P/OCF
P/OCF
Price to OCF
10.4
vs History
65
vs Industry
32
Median 3Y
10.2
Median 5Y
11.1
Industry
14
More Details
5.5
P/FCFE
P/FCFE
Price to FCFE
5.5
vs History
82
vs Industry
38
Median 3Y
16.8
Median 5Y
17.3
Industry
19.7
More Details
1.5
P/B
P/B
Price to Book Value
1.5
vs History
63
vs Industry
49
Median 3Y
1.5
Median 5Y
1.6
Industry
2.1
More Details
1.8
EV/S
EV/S
Enterprise Value to Sales
1.8
vs History
36
vs Industry
49
Median 3Y
1.4
Median 5Y
1.5
Industry
2.3
Forward
1.6
More Details
4.6
EV/GP
EV/GP
Enterprise Value to Gross Profit
4.6
vs History
36
vs Industry
44
Median 3Y
3.9
Median 5Y
4.1
Industry
4.8
More Details
12.6
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
12.6
vs History
38
vs Industry
25
Median 3Y
11.8
Median 5Y
11.9
Industry
11.5
Forward
9.4
More Details
12.6
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
12.6
vs History
38
vs Industry
32
Median 3Y
11.8
Median 5Y
11.9
Industry
15.7
Forward
11.8
More Details
12.2
EV/OCF
EV/OCF
Enterprise Value to OCF
12.2
vs History
42
vs Industry
30
Median 3Y
11.2
Median 5Y
11.9
Industry
14
More Details
15.2
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
15.2
vs History
65
vs Industry
27
Median 3Y
15.3
Median 5Y
16.3
Industry
17.4
More Details
1.2
EV/IC
EV/IC
Enterprise Value to IC
1.2
vs History
68
vs Industry
50
Median 3Y
1.2
Median 5Y
1.3
Industry
1.8
More Details

Multiples Across Competitors

ANN Competitors Multiples
Ansell Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
Market Cap P/S P/E EV/EBITDA EV/EBIT
AU
Ansell Ltd
ASX:ANN
4.4B AUD 1.5 25.4 12.6 12.6
CH
Alcon AG
SIX:ALC
34.4B CHF 4.2 37.5 17.3 32.7
JP
Hoya Corp
TSE:7741
5.9T JPY 6.8 29.1 17.9 21.3
DK
Coloplast A/S
CSE:COLO B
135.8B DKK 4.9 29.9 17.3 20.4
US
Align Technology Inc
NASDAQ:ALGN
13.2B USD 3.3 32.1 15.3 18.8
UK
ConvaTec Group PLC
LSE:CTEC
5.8B GBP 3.4 40.7 209.9 343.3
CH
Ypsomed Holding AG
SIX:YPSN
5.5B CHF 7.3 62.6 30.1 51.5
CN
Shenzhen New Industries Biomedical Engineering Co Ltd
SZSE:300832
45.9B CNY 13.1 32.9 28.4 28.4
US
Merit Medical Systems Inc
NASDAQ:MMSI
5.5B USD 4 44.9 20.7 36.2
US
Lantheus Holdings Inc
NASDAQ:LNTH
5.5B USD 3.6 21.5 9.9 11.3
KR
HLB Inc
KOSDAQ:028300
6.6T KRW 88.4 -35 -62.1 -58.7
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
AU
Ansell Ltd
ASX:ANN
Average EV/EBITDA: 37.9
12.6
27%
0.5
CH
Alcon AG
SIX:ALC
17.3
10%
1.7
JP
Hoya Corp
TSE:7741
17.9
9%
2
DK
Coloplast A/S
CSE:COLO B
17.3
9%
1.9
US
Align Technology Inc
NASDAQ:ALGN
15.3
15%
1
UK
ConvaTec Group PLC
LSE:CTEC
209.9
11%
19.1
CH
Ypsomed Holding AG
SIX:YPSN
30.1
31%
1
CN
Shenzhen New Industries Biomedical Engineering Co Ltd
SZSE:300832
28.4
18%
1.6
US
Merit Medical Systems Inc
NASDAQ:MMSI
20.7
12%
1.7
US
Lantheus Holdings Inc
NASDAQ:LNTH
9.9
21%
0.5
KR
H
HLB Inc
KOSDAQ:028300
Negative Multiple: -62.1 N/A N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
AU
Ansell Ltd
ASX:ANN
Average EV/EBIT: 57.7
12.6
18%
0.7
CH
Alcon AG
SIX:ALC
32.7
25%
1.3
JP
Hoya Corp
TSE:7741
21.3
N/A N/A
DK
Coloplast A/S
CSE:COLO B
20.4
9%
2.3
US
Align Technology Inc
NASDAQ:ALGN
18.8
17%
1.1
UK
ConvaTec Group PLC
LSE:CTEC
343.3
22%
15.6
CH
Ypsomed Holding AG
SIX:YPSN
51.5
40%
1.3
CN
Shenzhen New Industries Biomedical Engineering Co Ltd
SZSE:300832
28.4
16%
1.8
US
Merit Medical Systems Inc
NASDAQ:MMSI
36.2
28%
1.3
US
Lantheus Holdings Inc
NASDAQ:LNTH
11.3
22%
0.5
KR
H
HLB Inc
KOSDAQ:028300
Negative Multiple: -58.7 N/A N/A

See Also

Summary
ANN intrinsic value, competitors valuation, and company profile.
DCF Valuation
ANN stock valuation using Discount Cash Flow valuation method.
Relative Valuation
ANN stock valuation using valuation multiples.
Wall Street Estimates
ANN price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
ANN stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 262,500+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.